Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375528 | 0.88 | LPAR1 (0.42) | LPAR1FABP4FABP5PTGDR2SGMS2 | |
| SCHEMBL15402113 | 0.88 | L3MBTL1 (0.40) | LPAR1LMNAHTTHDAC8GAA | |
| SCHEMBL15401949 | 0.87 | PTGDR2 (0.44) | LPAR1FABP4FABP5PTGDR2FABP3 | |
| SCHEMBL15401682 | 0.87 | PTGDR2 (0.46) | FABP4FABP5PTGDR2SGMS2FABP3 | |
| SCHEMBL15402503 | 0.87 | PTGDR2 (0.49) | FABP4FABP5PTGDR2SGMS2FABP3 | |
| SCHEMBL15401975 | 0.87 | LMNA (0.43) | LPAR1FABP4FABP5LMNAKMT2A | |
| SCHEMBL15375472 | 0.81 | FABP4 (0.43) | LPAR1FABP4FABP5PTGDR2SGMS2 | |
| SCHEMBL15402604 | 0.81 | BCHE (0.38) | LPAR1FABP4FABP5KMT2AMEN1 | |
| SCHEMBL15401896 | 0.80 | PTGDR2 (0.46) | PTGDR2SGMS2LMNAHTTHDAC8 | |
| SCHEMBL15375550 | 0.79 | SGMS2 (0.41) | LPAR1FABP4FABP5PTGDR2SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | LPAR1 3283/4885FABP4 4349/4885FABP5 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.